AI Insight
Researchers at Johns Hopkins Kimmel Cancer Center have demonstrated that liquid biopsy blood tests detecting circulating tumor DNA can predict within weeks whether advanced non-small cell lung cancer patients are responding to immunotherapy. This approach could enable treatment decisions much earlier than current standard imaging methods, which typically require months to assess therapy effectiveness.
Why it matters
This predictive capability could allow physicians to discontinue ineffective immunotherapy treatments months earlier than currently possible, enabling faster transitions to alternative therapies that may better benefit patients. Earlier treatment adjustments could improve patient outcomes while reducing exposure to ineffective treatments and their associated side effects and costs.
Understand the Science
Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy determined that liquid biopsy—a blood test that detects circulating tumor DNA (ctDNA)—can predict, within a few weeks, whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy. This finding has the potential to facilitate early treatment decisions, allowing physicians to change therapies unlikely to benefit patients months sooner than is currently possible with standard imaging.
Source: Blood test predicts immunotherapy benefit early among patients with advanced lung cancer